COLORADO SPRINGS, Colo., July 24, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the three and six months ended June 30, 2014. Highlights of the quarter, all compared with the three months ended June 30, 2013 include:
- Revenue of $43.6 million, up 10%
- Vascular Intervention revenue of $22.5 million grew 19% (18% constant currency1), led by U.S. peripheral atherectomy revenue growth of 22%
- Lead Management revenue of $16.1 million increased 7% (6% constant currency)
- U.S. revenue grew 8% to $34.9 million; International revenue grew 22% (17% constant currency) to $8.7 million
- Gross margin increased to 76%, from 73%
- Closed AngioScore acquisition on June 30
"We had a strong second quarter with continued momentum in our vascular and international businesses. Lead management growth reflects our efforts to improve commercial execution and return to double digit growth in the fourth quarter. Two milestone achievements were recently accomplished in the form of the in-stent restenosis indication and the closing of the AngioScore acquisition. The growth prospects in front of us are profound and we are focused on execution," said Spectranetics President and Chief Executive Officer, Scott Drake.
Net loss for the three months ended June 30, 2014 was $6.6 million, or $0.16 per share, compared with a net loss of $728,000, or $0.02 per share, for the three months ended June 30, 2013. Non-GAAP net loss1, which excludes acquisition-related items, for the three months ended June 30, 2014 was $2.4 million, or $0.06 per share, compared with a non-GAAP net loss of $0.3 million, or $0.01 per share, for the three months ended June 30, 2013. Adjusted EBITDA1 was $780,000 for the three months ended June 30, 2014 compared with $2.1 million for the three months ended June 30, 2013.
_______________
| 1Constant currency, non-GAAP net loss, and Adjusted EBITDA are non-GAAP financial measures. See "Reconciliation of Non-GAAP Financial Measures" later in this release. |
Year-To-Date Financial Results
Revenue for the six months ended June 30, 2014 rose 8% (7% constant currency) to $83.2 million, from $77.1 million for the six months ended June 30, 2013. Vascular Intervention revenue increased 18% (17% constant currency) to $42.5 million, Lead Management revenue increased 1% to $30.6 million, and laser system, service and other revenue decreased 7% (8% constant currency) to $10.1 million.
On a geographic basis, revenue in the United States was $66.6 million, an increase of 6% from the six months ended June 30, 2013. International revenue totaled $16.5 million, an increase of 18% (14% constant currency) from the six months ended June 30, 2013.
Net loss during the six months ended June 30, 2014 was $12.2 million, or $0.29 per diluted share, compared with net loss of $1.7 million, or $0.05 per share, for the six months ended June 30, 2013. Non-GAAP net loss during the six months ended June 30, 2014 was $7.6 million, or $0.18 per share, compared with non-GAAP net loss of $0.9 million, or $0.02 per share, for the six months ended June 30, 2013. Adjusted EBITDA was a loss of $1.8 million for the six months ended June 30, 2014 compared with $3.4 million for the six months ended June 30, 2013.
2014 Outlook
Spectranetics management projects revenue for 2014 to be in the range of $198.5 million to $201.0 million, an increase of 25% to 27% over 2013. This includes a projected $27.0 million contribution from the recently acquired AngioScore products. Excluding the AngioScore revenue, organic revenue is anticipated to be in the range of $171.5 - $174.0 million, or 8% to 10% growth over 2013, which is consistent with our previous outlook. The organic revenue includes a modest contribution from the recently approved ISR indication and mechanical tools, offset by anticipated and inherent disruption associated with the integration of the AngioScore sales team.
Net loss for 2014 is projected to be in the range of $36.0 - $38.0 million, or $0.85 - $0.90 per share. Non-GAAP net loss for 2014 is projected to be in the range of $13.3 - $15.3 million, or $0.32 - $0.36 per share. Adjusted EBITDA is anticipated to be in the range of $0.0 - $2.0 million.
Conference Call
Management will host an investment community conference call today beginning at 2:30 p.m. MT / 4:30 p.m. ET. Individuals interested in listening to the conference call may dial (877) 561-2747 for domestic callers or (973) 409-9689 for international callers, or access the webcast on the investor relations section of the Company's Web site at: www.spectranetics.com. The webcast will be available on the Company's Web site for 14 days following the completion of the call.
About Spectranetics
Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
Spectranetics recently acquired AngioScore, Inc., a leading developer, manufacturer and marketer of cardiovascular, specialty balloons.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee as well as the AngioSculpt® scoring balloon used in both peripheral and coronary procedures. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not relate strictly to historical or current facts. Such statements may include words such as "anticipate," "will," "estimate," "expect," "look forward," "strive," "project," "intend," "should," "plan," "believe," "hope," "enable," "potential," and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, clinical trials, regulatory or competitive environments, our intellectual property and product development. These forward-looking statements include, but are not limited to, statements regarding our expectation of continued growth and strength and the reasons for that growth, growth rates, strength, and 2014 outlook including projected revenue, net loss and Adjusted EBITDA. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements and to note they speak only as of the date of this release. These risks and uncertainties may include financial results differing from guidance, inability to successfully integrate AngioScore into our business, market acceptance of excimer laser atherectomy technology and our vascular intervention and lead removal products, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of our strategic direction, dependence on new product development, loss of key personnel, uncertain success of or delays in our clinical trials, adverse results in any ongoing legal proceeding, or any legal proceeding in which we may become involved, adverse impact to our business of the health care reform and related legislation or regulations, including changes in reimbursements, continued or worsening adverse conditions in the general domestic and global economic markets and continued volatility and disruption of the credit markets, which affects the ability of hospitals and other health care systems to obtain credit and may impede our access to capital, intellectual property claims of third parties, availability of inventory from suppliers, adverse outcome of FDA inspections, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with any planned improvements to our manufacturing processes, and share price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause our actual results, performance or achievements to materially differ from any anticipated results, performance or achievements, please see our previously filed SEC reports, including those risks set forth in our 2013 Annual Report on Form 10-K. We disclaim any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures in this release. Reconciliations of the non-GAAP financial measures used in this release to the most directly comparable GAAP measures for the respective periods, and an explanation of our use of these non-GAAP measures, can be found in "Reconciliation of Non-GAAP Financial Measures" immediately following the financial tables. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.
-Financial tables follow-
| THE SPECTRANETICS CORPORATION | ||||
| Condensed Consolidated Statements of Operations | ||||
| (in thousands, except per share data and percentages) | ||||
| (unaudited) | ||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||
| 2014 | 2013 | 2014 | 2013 | |
| Revenue | $ 43,555 | $ 39,453 | $ 83,169 | $ 77,128 |
| Cost of products sold | 10,506 | 10,625 | 20,840 | 20,944 |
| Gross profit | 33,049 | 28,828 | 62,329 | 56,184 |
| Gross margin % | 76% | 73% | 75% | 73% |
| Operating expenses: | ||||
| Selling, general and administrative | 28,452 | 23,065 | 56,192 | 45,866 |
| Research, development and other technology | 5,704 | 5,484 | 11,791 | 10,656 |
| Due diligence, transaction, and integration costs | 3,958 | — | 4,229 | — |
| Medical device excise tax | 588 | 509 | 1,113 | 1,031 |
| Acquisition-related intangible asset amortization | 136 | 246 | 273 | 410 |
| Contingent consideration expense | 40 | 202 | 78 | 404 |
| Total operating expenses | 38,878 | 29,506 | 73,676 | 58,367 |
| Operating loss | (5,829) | (678) | (11,347) | (2,183) |
| Other income (expense), net | (490) | 14 | (486) | (15) |
| Loss before taxes | (6,319) | (664) | (11,833) | (2,198) |
| Income tax expense (benefit) | 246 | 64 | 393 | (511) |
| Net loss | $ (6,565) | $ (728) | $ (12,226) | $ (1,687) |
| Net loss per common share: | ||||
| Basic and diluted | $ (0.16) | $ (0.02) | $ (0.29) | $ (0.05) |
| Weighted average shares outstanding: | ||||
| Basic and diluted | 41,603 | 38,769 | 41,479 | 36,875 |
| THE SPECTRANETICS CORPORATION | ||
| Condensed Consolidated Balance Sheets | ||
| (in thousands) | ||
| (unaudited) | ||
| June 30, 2014 | December 31, 2013 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 107,027 | $ 128,395 |
| Accounts receivable, net | 38,045 | 26,766 |
| Inventories, net | 25,979 | 9,476 |
| Deferred income taxes, current portion, net | 445 | 445 |
| Other current assets | 4,193 | 2,748 |
| Total current assets | 175,689 | 167,830 |
| Property and equipment, net | 30,534 | 28,281 |
| Debt issuance costs, net | 7,421 | — |
| Goodwill and intangible assets | 261,311 | 20,455 |
| Other assets | 1,351 | 591 |
| Total assets | $ 476,306 | $ 217,157 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | $ 33,148 | $ 23,225 |
| Convertible senior notes | 230,000 | — |
| Other non-current liabilities | 30,045 | 3,932 |
| Stockholders' equity | 183,113 | 190,000 |
| Total liabilities and stockholders' equity | $ 476,306 | $ 217,157 |
| THE SPECTRANETICS CORPORATION | |||||
| Supplemental Financial Information | |||||
| (Unaudited) | |||||
| Financial Summary | 2013 | 2014 | |||
| (000's, except laser sales and installed base amounts) | 2nd Qtr | 3rd Qtr | 4th Qtr | 1st Qtr | 2nd Qtr |
| Disposable products revenue: | |||||
| Vascular Intervention revenue | $ 18,897 | $ 18,956 | $ 20,555 | $ 20,021 | $ 22,496 |
| Lead Management revenue | 15,078 | 16,075 | 16,286 | 14,470 | 16,114 |
| Total disposable products revenue | 33,975 | 35,031 | 36,841 | 34,491 | 38,610 |
| Service and other revenue | 2,888 | 2,851 | 2,795 | 2,769 | 2,872 |
| Laser revenue: | |||||
| Equipment sales | 1,395 | 906 | 1,153 | 1,530 | 1,191 |
| Rental fees | 1,195 | 975 | 1,131 | 824 | 882 |
| Total laser revenue | 2,590 | 1,881 | 2,284 | 2,354 | 2,073 |
| Total revenue | 39,453 | 39,763 | 41,920 | 39,614 | 43,555 |
| Net income (loss) | (728) | 434 | 883 | (5,661) | (6,565) |
| Adjusted EBITDA (1) | 2,147 | 3,784 | 3,984 | (2,610) | 777 |
| Cash flow generated by (used in) operating activities | 2,048 | 3,513 | 5,029 | (8,359) | (1,111) |
| Total cash and cash equivalents at end of quarter | 119,356 | 123,570 | 128,395 | 120,866 | 107,027 |
| Laser sales summary: | |||||
| Laser sales from inventory | 9 | 9 | 5 | 9 | 8 |
| Laser sales from evaluation/rental units | 5 | — | 5 | 4 | 1 |
| Total laser sales | 14 | 9 | 10 | 13 | 9 |
| (1) Adjusted EBITDA is a non-GAAP financial measure. Please refer to the non-GAAP reconciliation tables following this table for the reconciliation to the most comparable GAAP measure. | |||||
| Worldwide Installed Base Summary: | |||||
| Laser sales from inventory | 9 | 9 | 5 | 9 | 8 |
| Rental placements | 28 | 27 | 29 | 20 | 32 |
| Evaluation placements | 11 | 4 | 9 | 8 | 6 |
| Laser placements during quarter | 48 | 40 | 43 | 37 | 46 |
| Buy-backs/returns during quarter | (23) | (26) | (18) | (17) | (15) |
| Net laser placements during quarter | 25 | 14 | 25 | 20 | 31 |
| Total lasers placed at end of quarter | 1,105 | 1,119 | 1,144 | 1,164 | 1,195 |
Reconciliation of Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements prepared in accordance with GAAP, we use certain non-GAAP financial measures in this release. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures for the respective periods can be found in the tables below. An explanation of the manner in which our management uses these non-GAAP measures to conduct and evaluate our business and the reasons management believes these non-GAAP measures provide useful information to investors are provided following the reconciliation tables.
| THE SPECTRANETICS CORPORATION | ||||||
| Reconciliation of revenue by geography to non-GAAP revenue by geography | ||||||
| on a constant currency basis | ||||||
| (in thousands, except percentages) | ||||||
| (unaudited) | ||||||
| Three Months Ended | ||||||
| June 30, 2014 | June 30, 2013 | Change | ||||
|
Revenue, as reported |
Foreign exchange impact as compared to prior period |
Revenue on a constant currency basis |
Revenue, as reported |
As reported |
Constant currency basis |
|
| United States | $ 34,854 | $ — | $ 34,854 | $ 32,310 | 8% | 8% |
| International | 8,701 | (329) | 8,372 | 7,143 | 22% | 17% |
| Total revenue | $ 43,555 | $ (329) | $ 43,226 | $ 39,453 | 10% | 10% |
| Six Months Ended | ||||||
| June 30, 2014 | June 30, 2013 | Change | ||||
|
Revenue, as reported |
Foreign exchange impact as compared to prior period |
Revenue on a constant currency basis |
Revenue, as reported |
As reported |
Constant currency basis |
|
| United States | $ 66,626 | $ — | $ 66,626 | $ 63,101 | 6% | 6% |
| International | 16,543 | (508) | 16,035 | 14,027 | 18% | 14% |
| Total revenue | $ 83,169 | $ (508) | $ 82,661 | $ 77,128 | 8% | 7% |
| THE SPECTRANETICS CORPORATION | ||||||
| Reconciliation of revenue by product line to non-GAAP revenue by product line | ||||||
| on a constant currency basis | ||||||
| (in thousands, except percentages) | ||||||
| (unaudited) | ||||||
| Three Months Ended | ||||||
| June 30, 2014 | June 30, 2013 | Change | ||||
|
Revenue, as reported |
Foreign exchange impact as compared to prior period |
Revenue on a constant currency basis |
Revenue, as reported |
As reported |
Constant currency basis |
|
| Vascular Intervention | $ 22,496 | $ (108) | $ 22,388 | $ 18,897 | 19% | 18% |
| Lead Management | 16,114 | (164) | 15,950 | 15,078 | 7% | 6% |
| Laser System, Service & Other | 4,945 | (57) | 4,888 | 5,478 | (10)% | (11)% |
| Total revenue | $ 43,555 | $ (329) | $ 43,226 | $ 39,453 | 10% | 10% |
| Six Months Ended | ||||||
| June 30, 2014 | June 30, 2013 | Change | ||||
|
Revenue, as reported |
Foreign exchange impact as compared to prior period |
Revenue on a constant currency basis |
Revenue, as reported |
As reported |
Constant currency basis |
|
| Vascular Intervention | $ 42,517 | $ (162) | $ 42,355 | $ 36,090 | 18% | 17% |
| Lead Management | 30,584 | (249) | 30,335 | 30,157 | 1% | 1% |
| Laser System, Service & Other | 10,068 | (97) | 9,971 | 10,881 | (7)% | (8)% |
| Total revenue | $ 83,169 | $ (508) | $ 82,661 | $ 77,128 | 8% | 7% |
| THE SPECTRANETICS CORPORATION | ||||
| Reconciliation of Net Loss to Non-GAAP Net Loss | ||||
| (in thousands) | ||||
| (unaudited) | ||||
| Three Months Ended | Six Months Ended | |||
| June 30, 2014 | June 30, 2013 | June 30, 2014 | June 30, 2013 | |
| Net loss, as reported | $ (6,565) | $ (728) | $ (12,226) | $ (1,687) |
| Due diligence, transaction, and integration costs (1) | 3,958 | — | 4,229 | — |
| Acquisition-related intangible asset amortization (2) | 136 | 246 | 273 | 410 |
| Contingent consideration expense (2) | 40 | 202 | 78 | 404 |
| Non-GAAP net loss | $ (2,431) | $ (280) | $ (7,646) | $ (873) |
| Reconciliation of Net Loss Per Share to Non-GAAP Net Loss Per Share | ||||
| (unaudited) | ||||
| Three Months Ended | Six Months Ended | |||
| June 30, 2014 | June 30, 2013 | June 30, 2014 | June 30, 2013 | |
| Net loss per share, as reported | $ (0.16) | $ (0.02) | $ (0.29) | $ (0.05) |
| Due diligence, transaction, and integration costs (1) | 0.10 | — | 0.10 | — |
| Acquisition-related intangible asset amortization (2) | — | 0.01 | 0.01 | 0.01 |
| Contingent consideration expense (2) | — | 0.01 | — | 0.01 |
| Non-GAAP net loss per share (3) | $ (0.06) | $ (0.01) | $ (0.18) | $ (0.02) |
| Reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA | |||||
| (in thousands) | |||||
| (unaudited) | |||||
| Three Months Ended | |||||
| June 30, 2013 | September 30, 2013 | December 31, 2013 | March 31, 2014 | June 30, 2014 | |
| Net income (loss), as reported | $ (728) | $ 434 | $ 883 | $ (5,661) | $ (6,565) |
| Income tax expense (benefit) | 64 | 406 | 885 | 147 | 246 |
| Interest expense (income), net | (6) | 1 | (2) | (1) | 489 |
| Depreciation and amortization | 2,369 | 2,463 | 2,419 | 2,459 | 2,473 |
| Acquisition-related intangible asset amortization (2) | 246 | 246 | 245 | 137 | 136 |
| EBITDA | 1,945 | 3,550 | 4,430 | (2,919) | (3,221) |
| Contingent consideration expense (2) | 202 | 234 | 229 | 38 | 40 |
| Due diligence, transaction, and integration costs (1) | — | — | — | 271 | 3,958 |
| Intangible asset impairment and change in contingent consideration liability, net (2) | — | — | (675) | — | — |
| Adjusted EBITDA (4) | $ 2,147 | $ 3,784 | $ 3,984 | $ (2,610) | $ 777 |
| THE SPECTRANETICS CORPORATION | ||
| Reconciliation of Net Loss to EBITDA and Adjusted EBITDA | ||
| (in thousands) | ||
| (unaudited) | ||
| Six Months Ended | ||
| June 30, 2014 | June 30, 2013 | |
| Net loss, as reported | $ (12,226) | $ (1,687) |
| Income tax expense (benefit) | 393 | (511) |
| Interest expense (income), net | 488 | (2) |
| Depreciation and amortization | 4,932 | 4,823 |
| Acquisition-related intangible asset amortization (2) | 273 | 410 |
| EBITDA | (6,140) | 3,033 |
| Contingent consideration expense (2) | 78 | 404 |
| Due diligence, transaction, and integration costs (1) | 4,229 | — |
| Adjusted EBITDA (4) | $ (1,833) | $ 3,437 |
| __________________ | ||
| 1) Due diligence, transaction, and integration costs are related to the AngioScore acquisition, which closed on June 30, 2014, and primarily included investment banking fees, accounting, consulting, and legal fees. | ||
| 2) Acquisition-related intangible asset amortization relates to intangible assets acquired from Upstream Peripheral Technologies Ltd. ("Upstream") in January 2013. Contingent consideration expense represents the accretion of the estimated contingent consideration liability related to amounts payable to Upstream in 2014, 2015 and 2016, primarily based on sales of the products acquired. In the fourth quarter of 2013, we remeasured the contingent consideration liability to its fair value and reduced it by approximately $5.2 million and recorded an impairment charge of approximately $4.5 million related to the intangible assets acquired. | ||
| 3) Per share amounts may not add due to rounding. | ||
| 4) In 2014, we are not adding back the medical device excise tax to Adjusted EBITDA, as the tax was also included in 2013 results. Therefore, the 2013 quarterly Adjusted EBITDA numbers have been restated to include the medical device excise tax. | ||
| Reconciliation of 2014 Projected Net Loss to Non-GAAP Projected Net Loss | ||
| (in millions) | ||
| (unaudited) | ||
| Projected Range | ||
| Twelve Months Ended | ||
| December 31, 2014 | December 31, 2014 | |
| Net loss, GAAP | $ (38.0) | $ (36.0) |
| Acquisition-related amortization & contingent consideration expense (5) | 10.7 | 10.7 |
| Due diligence, transaction, and integration costs (1) | 9.5 | 9.5 |
| Litigation costs (6) | 2.5 | 2.5 |
| Non-GAAP net loss | $ (15.3) | $ (13.3) |
| THE SPECTRANETICS CORPORATION | ||
| Reconciliation of 2014 Projected Net Loss Per Share to Non-GAAP Projected Net Loss Per Share | ||
| (unaudited) | ||
| Projected Range | ||
| Twelve Months Ended | ||
| December 31, 2014 | December 31, 2014 | |
| Net loss per share, GAAP | $ (0.90) | $ (0.85) |
| Acquisition-related amortization & contingent consideration expense (5) | 0.25 | 0.25 |
| Due diligence, transaction, and integration costs (1) | 0.23 | 0.23 |
| Litigation costs (6) | 0.06 | 0.06 |
| Non-GAAP net loss per share (3) | $ (0.36) | $ (0.32) |
| Reconciliation of 2014 Projected Net Loss to EBITDA and Adjusted EBITDA | ||
| (in millions) | ||
| (unaudited) | ||
| Projected Range | ||
| Twelve Months Ended | ||
| December 31, 2014 | December 31, 2014 | |
| Net loss, GAAP | $ (38.0) | $ (36.0) |
| Income tax expense | 0.9 | 0.9 |
| Interest expense, net | 4.0 | 4.0 |
| Depreciation and amortization | 10.4 | 10.4 |
| Acquisition-related amortization (5) | 8.4 | 8.4 |
| EBITDA | (14.3) | (12.3) |
| Contingent consideration expense (5) | 2.3 | 2.3 |
| Due diligence, transaction, and integration costs (1) | 9.5 | 9.5 |
| Litigation costs (6) | 2.5 | 2.5 |
| Adjusted EBITDA | $ — | $ 2.0 |
| __________________ | ||
| 5) Acquisition-related amortization includes amortization of intangible assets acquired from Upstream in 2013 and from AngioScore in 2014, and amortization of the step-up in fair value of AngioScore inventory. Contingent consideration expense includes accretion on the contingent consideration liabilities incurred in both the Upstream and the AngioScore acquisitions. | ||
| 6)Litigation costs represent legal costs in a patent-related matter in which AngioScore is the plaintiff. | ||
Management uses the non-GAAP financial measures as supplemental measures to analyze the underlying trends in our business, assess the performance of our core operations, establish operational goals and forecasts that are used in allocating resources and evaluate our performance period over period and in relation to our competitors' operating results.
The impact of foreign exchange rates is highly variable and difficult to predict. We use a constant currency basis to show the impact from foreign exchange rates on current period revenue compared to prior period revenue using the prior period's foreign exchange rates. In order to properly understand the underlying business trends and performance of our ongoing operations, we believe that investors may find it useful to consider the impact of excluding changes in foreign exchange rates from our revenue.
We believe presenting the non-GAAP financial measures used in this release provides investors greater transparency to the information used by our management for financial and operational decision-making and allows investors to see our results "through the eyes" of management. We also believe providing this information better enables our investors to understand our operating performance and evaluate the methodology used by management to evaluate and measure such performance.
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Some limitations associated with using these non-GAAP financial measures are provided below:
- Management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures used.
- Depreciation and amortization expense, while not requiring cash settlement, are ongoing and recurring expenses and have a material impact on GAAP net income and reflect economic costs to us not reflected in Adjusted EBITDA. The intangible asset impairment, while not requiring cash settlement, reflects an economic cost to us not reflected in Adjusted EBITDA.
- Items such as the due diligence, transaction and integration costs, litigation costs, and contingent consideration expense excluded from Adjusted EBITDA and Non-GAAP Net Loss can have a material impact on cash flows and GAAP net income and reflect economic costs to us not reflected in Adjusted EBITDA.
- Revenue growth rates stated on a constant currency basis, by their nature, exclude the impact of changes in foreign currency exchange rates, which may have a material impact on GAAP revenue.
- Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.